ACID CONCENTRATE RO4138 6.635 G
ACETIC ACID : 6.635 G DEXTROSE : 40.51 G MAGNESIUM CHLORIDE : 3.744 G SODIUM CHLORIDE : 226 G CALCIUM CHLORIDE : 6.769 G POTASSIUM CHLORIDE : 5.491 G · DIN 02179113 · GENPHARM ULC
Health Canada status: CANCELLED POST MARKET
What is ACID CONCENTRATE RO4138?
ACID CONCENTRATE RO4138 6.635 G contains ACETIC ACID : 6.635 G DEXTROSE : 40.51 G MAGNESIUM CHLORIDE : 3.744 G SODIUM CHLORIDE : 226 G CALCIUM CHLORIDE : 6.769 G POTASSIUM CHLORIDE : 5.491 G. It is listed in the Health Canada Drug Product Database under DIN 02179113, held by GENPHARM ULC, supplied as LIQUID for HAEMODIALYSIS administration. Health Canada currently lists it as cancelled post market, status dated 30-Jul-2004. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02179113 |
|---|---|
| Brand name | ACID CONCENTRATE RO4138 |
| Generic / active ingredient | ACETIC ACID : 6.635 G DEXTROSE : 40.51 G MAGNESIUM CHLORIDE : 3.744 G SODIUM CHLORIDE : 226 G CALCIUM CHLORIDE : 6.769 G POTASSIUM CHLORIDE : 5.491 G |
| Manufacturer | GENPHARM ULC |
| Strength | 6.635 G |
| Dosage form | LIQUID |
| Route of administration | HAEMODIALYSIS |
| Schedule | Ethical |
| ATC code | B05ZA HEMODIALYTICS, CONCENTRATES |
| AHFS class | 40:34.00* ; See footnote |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-Jul-2004 |
| Original market date | 1995-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code B05ZA HEMODIALYTICS, CONCENTRATES. 117 of 588 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACID CONCENTRATE 2156 | 10.1 G | SOLUTION | VANTIVE ULC | MARKETED | DIN 02239491 |
| ACID CONCENTRATE 2182 | 262.98 G | SOLUTION | VANTIVE ULC | MARKETED | DIN 02210835 |
| ACID CONCENTRATE A1221 | 3.35 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254344 |
| ACID CONCENTRATE A1222 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254336 |
| ACID CONCENTRATE A1223 | 9.92 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254328 |
| ACID CONCENTRATE A1224 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254301 |
| ACID CONCENTRATE A1225 | 263.0 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254298 |
| ACID CONCENTRATE A1226 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254255 |
| ACID CONCENTRATE A1227 | 8.27 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254247 |
| ACID CONCENTRATE A1228 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02533774 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.